Fig. 5: CRISPR identification of targetable essential kinases leads to a more effective combination therapy consisting of indisulam and an ATR inhibitor.
From: RBM39 degrader invigorates innate immunity to eradicate neuroblastoma despite cancer cell plasticity
a Human Kinase CRISPR library screening using SK-N-AS cell lines derived from naïve tumors and indisulam-resistant tumors in the presence of absence of 250 nM of indisulam. b Venn diagram showing the shared and cell-type-specific essential kinases. c Kaplan-Meier survival for SK-N-AS tumors treated with vehicle (n = 5), indisulam (n = 5), gartisertib (n = 5), or combination (n = 5). Indisulam is administered with 10 mg/kg, 5 days on, 2 days off, for 3 weeks, with an additional two weeks when tumors relapse with indisulam alone treatment. Gartisertib is administered with 10 mg/kg, once weekly. **p = 0.02, which is calculated by the Log-rank (Mantel-Cox) test. d Body weight monitoring over time for each individual mouse. Source data are provided as a Source Data file.
